Patents Assigned to Pharmadigm, Inc.
  • Patent number: 6187767
    Abstract: The present invention is related to a method for preventing or reducing the effects of ischemia. The ischemia may be associated with injury or reperfusion injury, such as occurs as a result of infarctions, thermal injury (burns), surgical trauma, accidental trauma, hemorrhagic shock and the like. The invention is also related to methods for preventing or reducing bacterial translocation, adult respiratory distress syndrome, adherence of blood cells and platelets to endothelial cells and pulmonary hypertension. In accordance with the present invention, these conditions are prevented or reduced by administering a dehydroepiandrosterone (DHEA) derivative as defined herein.
    Type: Grant
    Filed: May 14, 1999
    Date of Patent: February 13, 2001
    Assignees: University of Utah Research Foundation, Pharmadigm, Inc.
    Inventors: Barbara A. Araneo, Raymond A. Daynes, Urszula Orlinska, Imad S. Farrukh
  • Patent number: 6150348
    Abstract: The present invention is related to a method for preventing or reducing the effects of ischemia. The ischemia may be associated with injury or reperfusion injury, such as occurs as a result of infarctions, thermal injury (burns), surgical trauma, accidental trauma, hemorrhagic shock and the like. The invention is also related to methods for preventing or reducing bacterial translocation, adult respiratory distress syndrome, adherence of blood cells and platelets to endothelial cells and pulmonary hypertension. In accordance with the present invention, these conditions are prevented or reduced by administering a dehydroepiandrosterone (DHEA) derivative as defined herein.
    Type: Grant
    Filed: May 14, 1999
    Date of Patent: November 21, 2000
    Assignees: University of Utah Research Foundation, Pharmadigm, Inc.
    Inventors: Barbara A. Araneo, Raymond A. Daynes, Urszula Orlinska, Imad S. Farrukh
  • Patent number: 5977095
    Abstract: The present invention is related to a method for preventing or reducing the effects of ischemia. The ischemia may be associated with injury or reperfusion injury, such as occurs as a result of infarctions, thermal injury (bums), surgical trauma, accidental trauma, hemorrhagic shock and the like. The invention is also related to methods for preventing, or reducing bacterial translocation, adult respiratory distress syndrome, adherence of blood cells and platelets to endothelial cells and pulmonary hypertension. In accordance with the present invention, these conditions are prevented or reduced by administering a dehydroepiandrosterone (DHEA) derivative as defined herein.
    Type: Grant
    Filed: June 5, 1997
    Date of Patent: November 2, 1999
    Assignees: University of Utah Research Foundation, Pharmadigm, Inc.
    Inventors: Barbara A. Araneo, Raymond A. Daynes, Urszula Orlinska, Imad S. Farrukh
  • Patent number: 5859000
    Abstract: The present invention is directed to a method for reducing mast cell mediated allergic reactions, including mast cell mediated allergy and asthma. Mast cell mediated allergic reactions, including type I hypersensitivity reasponse to allergens and asthma, are reduced by administering a dehydroepiandrosterone (DHEA) derivative to a patient in a manner which quickly raises blood levels of the active agent.
    Type: Grant
    Filed: November 7, 1997
    Date of Patent: January 12, 1999
    Assignees: University of Utah Research Foundation, Pharmadigm, Inc.
    Inventors: Tad Dowell, Steven D. Norton, Barbara A. Araneo
  • Patent number: 5846963
    Abstract: The present invention is related to a method for preventing or reducing the effects of ischemia. The ischemia may be associated with injury or reperfusion injury, such as occurs as a result of infarctions, thermal injury (burns), surgical trauma, accidental trauma, hemorrhagic shock and the like. The invention is also related to methods for preventing or reducing bacterial translocation, adult respiratory distress syndrome, adherence of blood cells and platelets to endothelial cells and pulmonary hypertension. In accordance with the present invention, these conditions are prevented or reduced by administering dehydroepiandrosterone-3-sulfate (DHEAS).
    Type: Grant
    Filed: August 18, 1995
    Date of Patent: December 8, 1998
    Assignees: University of Utah Research Foundation, Pharmadigm, Inc.
    Inventors: Barbara A. Araneo, Urszula Orlinska, Imad S. Farrukh
  • Patent number: 5795872
    Abstract: The present invention is directed to a DNA construct which is useful for immunization or gene therapy. The construct of the invention comprises muscle specific regulatory elements, such as a promoter or a promoter and one or more enhancer elements, and a DNA sequence under control of the muscle specific regulatory elements. Several DNA sequences may be incorporated into the DNA construct. In one embodiment, the DNA sequence codes for an antigen, antigenic determinant or an epitope of an antigen. In a second embodiment, the DNA sequence is a normal muscle gene which is effected in a muscle disease. In a third embodiment, the DNA sequence is an antisense for blocking an abnormal muscle gene. In a fourth embodiment, the DNA sequence codes for a protein which circulates in the mammalian blood or lymphatic systems.
    Type: Grant
    Filed: September 19, 1995
    Date of Patent: August 18, 1998
    Assignee: Pharmadigm, Inc.
    Inventors: Joseph W. Ricigliano, Barbara A. Araneo
  • Patent number: 5753640
    Abstract: The present invention is related to a method for preventing or reducing the effects of ischemia. The ischemia may be associated with injury or reperfusion injury, such as occurs as a result of infarctions, thermal injury (burns), surgical trauma, accidental trauma, hemorrhagic shock and the like. The invention is also related to methods for preventing or reducing bacterial translocation, adult respiratory distress syndrome, adherence of blood cells and platelets to endothelial cells and pulmonary hypertension. In accordance with the present invention, these conditions are prevented or reduced by administering dehydroepiandrosterone-3-sulfate (DHEAS), DHEA or a DHEA congener.
    Type: Grant
    Filed: December 29, 1995
    Date of Patent: May 19, 1998
    Assignees: University of Utah Research Foundation, Pharmadigm, Inc.
    Inventors: Barbara A. Araneo, Urszula Orlinska, Imad S. Farrukh